Navigation Links
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Date:6/8/2009

-Hodgkin's lymphoma (63% ORR), Hodgkin's disease (53% ORR), follicular lymphoma (50% ORR), mantle cell lymphoma (32% ORR), DLBCL (30% ORR) and small lymphocytic lymphoma (18% ORR)(1).

Patients received everolimus 10 mg daily and were evaluated monthly. Dose reductions to 5 mg daily and 5 mg every other day were permitted. Response was assessed after two cycles of treatment and periodically thereafter. Patients received a median of three cycles(1). Overall, everolimus was well tolerated. The most commonly reported adverse events (grade 3 or 4; >10% patients) in this heavily pretreated population included anemia, neutropenia and thrombocytopenia(1).

About non-Hodgkin's lymphoma and Hodgkin's disease

Non-Hodgkin's lymphoma and Hodgkin's disease manifest in the cells of the lymphatic system, which is composed of lymphoid tissue, lymph vessels and lymph fluid that help the body filter out bacteria and fight disease. Since lymphatic tissue is located throughout the body, NHL and Hodgkin's disease can start almost anywhere(2,7,8). The most recent data indicate that more than 300,000 new cases of NHL develop around the world each year(9).

About Afinitor

Afinitor has been approved by the US Food and Drug Administration (FDA) as the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. Recently, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting EU approval of Afinitor to treat patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Novartis has also filed regulatory su
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... OncoSec Medical Incorporated (OTCBB: ONCS), which is ... solid tumor cancers, announced today clinical study results ... Future of Ablation Therapies conference in Las Vegas, ... titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors ...
... Nonin Medical, Inc., the inventor of finger pulse ... announced the launch of the Onyx® Vantage 9590 professional ... 2011 Annual Congress in The Netherlands. The Onyx® Vantage ... the presence of low perfusion. The new device features ...
Cached Medicine Technology:Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 2Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 3Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 4Nonin Medical Launches Onyx® Vantage 9590 Professional Finger Pulse Oximeter at ERS Annual Congress 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... ... Awards Ceremony Reminded Everyone of the Importance of One Simple Thing: Good Posture. ... (PRWEB) March 11, ... poor posture of some presenters than on the Vera Wang dresses or breakout performances ...
... ... of $25 or more for all hand and body lotions as well as facial serums. ... Southfield, Mich. (PRWEB) March ... lotions with an emphasis on the key ingredient African Shea butter. The products are highly ...
... ... few weeks, thousands of college students across the U.S. will travel abroad ... abusive drinking. Kathleen Quartaro, a Choose Responsibility volunteer and mother of a ... drinking during her freshman year, urges parents and students to discuss the ...
... ... put an end to decades of unethical and disinterested leadership in Northern Manhattan by supporting ... ... 2010 -- After decades of serving the men and women of New York City through ...
... ... Houston and will soon be expanding nationwide. Local IT Companies connects businesses with up to ... , ... It seems most business owners are entrenched in their own day to day business building ...
... ... company that takes pride in providing accurate information on sexuality and toys for grown-ups, ... , ... March 11, 2010 -- Good Vibrations , the legendary San Francisco-based company that takes ...
Cached Medicine News:Health News:Slouching Stars at the Oscars: Could the PostureNOW Posture Brace Have Helped Miley? 2Health News:Free Shipping On Hand and Body Lotions Made with African Shea Butter 2Health News:Mother of Binge Drinking Victim Urges Students and Parents to Discuss Signs of Alcohol Poisoning, Emphasize Peer Responsibility Prior to Spring Break 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 3Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Good Vibrations' Pleasure-Ed Series Brings High Quality Erotic Education to the Classroom and the Bedroom 2
... Healthcare is known as ... analysis programs for every ... device. With advanced programs ... and ACI-TIPI, GE can ...
For use in vitreo-retinal procedures with a non contact system, and compatible with the Oculus BIOM system, this lens delivers the highest image clarity available in a non contact surgical lens....
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
... family features St. Jude Medical's ... lead is available in both ... silicone (IsoFlex S lead) models, ... and multiple lead lengths, providing ...
Medicine Products: